Across TCGA pan-cancer cohorts, MIR891A RNA is linked to patient survival in 1 of 34 cancer types, making it the most broadly survival-associated MIR891A data layer compared with 1 for mutation status.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MIR891A RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR891A expression acts as an unfavorable survival marker.
UCEC are the cancer types where MIR891A RNA most reproducibly stratifies survival.